Program
KN060
A development code. Also written as “KN060 Low”, “KN060 Middle” and “KN060 Hight”.
Its studies are mostly in Kidney Failure, Chronic · Essential Hypertension, led by Suzhou Alphamab.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Suzhou Alphamab | 33 open or running | phase 2since Dec 3, 2023 | Dec 3, 2023 | Dec 30, 2026phase 1 · NCT07191899 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 3, 2023First study: phase 2 study in Knee Arthroplasty, TotalFirst studyNCT06180889 · 241 enrolled · China
- Jun 6, 2025Phase 1 study in HypertensionNCT07191899 · 60 planned · China
- Sep 16, 2025Phase 2 study in End-Stage Renal Disease Requiring HaemodialysisNCT07201467 · 12 planned · China
Ahead
- Dec 30, 2026Primary completion: phase 1 study in HypertensionNCT07191899
- Aug 15, 2027Primary completion: phase 2 study in End-Stage Renal Disease Requiring HaemodialysisNCT07201467
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07201467End-Stage Renal Disease Requiring Haemodialysis · China | 2 | Recruiting | Aug 15, 2027 | 12 |
| NCT07191899Hypertension · China | 1 | Recruiting | Dec 30, 2026 | 60 |
| NCT06180889Knee Arthroplasty, Total · China | 2 | Active, not recruiting | Dec 15, 2025 | 241 |
How it is read
Names in the registry
- “KN060”, 2 entries
- “KN060 Low”, 1 entry
- “KN060 Middle”, 1 entry
- “KN060 Hight”, 1 entry
Codes read as this program: KN060.
Conditions, from the studies’ own filings
- Kidney Failure, Chronic, 1 study
- Essential Hypertension, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.